Enveda Biosciences is a technology company.
Enveda Biosciences has raised $442.0M across 6 funding rounds.
Enveda Biosciences has raised $442.0M in total across 6 funding rounds.
Enveda Biosciences has raised $442.0M in total across 6 funding rounds.
Enveda Biosciences's investors include Builders VC, Dimension Capital, DN Capital, FPV Fund, Global Founders Capital, Hummingbird Ventures, Icebreaker.vc, Kinnevik, True Ventures, Chris Gibson, Henry Kravis, rajiv chegu.
Enveda Biosciences is a clinical-stage biotechnology company revolutionizing small molecule drug discovery by harnessing the chemical diversity of nature through AI, mass spectrometry, robotics, and machine learning.[1][2][3][5][6] It builds a searchable platform that maps millions of previously unknown plant-derived molecules, enabling 4x faster discovery at 1/10th the industry cost, targeting diseases like atopic dermatitis, asthma, obesity, and liver diseases.[1][3][5] Serving pharmaceutical developers and patients, Enveda solves the longstanding inefficiency of natural product drug discovery—once the source of nearly half of all pill-form medicines but abandoned by big pharma due to slow, costly processes—by creating the world's largest library of plant molecules and advancing 16 preclinical programs, 12 development candidates, four IND-enabling assets, and one in Phase 1b trials.[1][2][3][5][6] With over 170 employees, $175M raised since 2019, and rapid momentum including a 230% speed increase in discovery via tools like Benchling, Enveda is a fast-scaling TechBio leader.[2][4]
Founded in 2019 by molecular biologist Viswa Colluru, previously at Recursion Pharmaceuticals, Enveda emerged from the insight that nature holds untapped drug answers despite historical successes like plant-derived medicines, but traditional methods were too slow and inefficient.[1][2] Colluru and the team challenged the pharma industry's shift away from natural products, innovating under constraints by building an early platform to map chemical knowledge from metabolomics data, then expanding to high-throughput screening and structure prediction.[2][5] Pivotal early traction came from sourcing high-potential plants, cataloging molecules via mass spectrometry and AI, and scaling to a global team of 170, with Kinnevik noting its generation of 16 preclinical programs in five years as a key milestone.[1][2]
Enveda's edge lies in its integrated platform that revives and scales natural product discovery:
Enveda rides the TechBio wave, merging AI with biology to unlock "dark chemical space" in nature, addressing pharma's productivity crisis where natural products—origin of nearly half of medicines—were sidelined.[1][2][3][6] Timing is ideal amid AI foundation models and exponential data growth, enabling Enveda to outpace traditional phenotypic screening (e.g., Recursion) by prioritizing chemical prioritization over imaging.[2][5] Market forces like rising demand for novel small molecules against undruggable targets, plus investor enthusiasm (e.g., Kinnevik, $175M raised), favor its model, influencing the ecosystem by re-energizing natural product discovery, validating AI-metabolomics for startups, and potentially expanding to non-pharma fields like nutrition.[1][2][3][5]
Enveda is poised to hit critical milestones, advancing atopic dermatitis, asthma, obesity, and liver programs to Phase 2+ trials or partnerships within 1-2 years, while scaling its platform for broader applications.[1] Trends like AI-driven drug discovery acceleration and programmable chemistry will propel it, potentially redefining small molecule success rates from "surprise" to "default."[2][5] Its influence may evolve from niche innovator to ecosystem shaper, partnering assets for value and inspiring TechBio contrarians. This positions Enveda to deliver on its mission of hope through nature's evolutionary intelligence, transforming untapped chemistry into life-saving drugs.[6]
Enveda Biosciences has raised $442.0M across 6 funding rounds. Most recently, it raised $150.0M Series D in September 2025.